| Dr Lin Shen, MD, PHD | |
|
400 Parnassus Ave # U384, San Francisco, CA 94143-2202 | |
| (415) 353-2497 | |
| Not Available |
| Full Name | Dr Lin Shen |
|---|---|
| Gender | Female |
| Speciality | Rheumatology |
| Experience | 19 Years |
| Location | 400 Parnassus Ave # U384, San Francisco, California |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1518266006 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RR0500X | Internal Medicine - Rheumatology | A130229 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| The University Of Chicago Medical Center | Chicago, IL | Hospital |
| Ucsf Medical Center | San francisco, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ucsf Medical Group Business Services | 3779497870 | 1064 |
| The University Of Chicago Medical Center | 7618880766 | 754 |
News Archive
Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that Dr. Geoffrey I. Shapiro of Dana-Farber Cancer Institute, presented preclinical and clinical data on STA-9090, a potent second-generation Hsp90 inhibitor, at IASLC (International Association for the Study of Lung Cancer) 10th Annual Targeted Therapies of the Treatment of Lung Cancer Meeting in Santa Monica, CA.
The authors of the bestselling EAT THIS, NOT THAT! book series, with more than five million copies in print, today released the ultimate reference book for making the most effective food choices while dining at your favorite restaurants — EAT THIS, NOT THAT! RESTAURANT SURVIVAL GUIDE by David Zinczenko, with Matt Goulding.
Olivier Delattre's team (Inserm Unit 830 "Genetics and Biology of Cancer") of the Institut Curie reveal in an article in the 16 October issue of Nature that alteration of the ALK gene is closely associated with the most frequent solid extracerebral tumor in children-neuroblastoma. By studying the familial forms of this tumor, the researchers also conclude that ALK is a gene that predisposes to neuroblastoma.
Using a first-of-its-class drug in a clinical trial, an international research effort headed by a scientist at University of California San Diego School of Medicine reports that inhibition of a key enzyme safely and effectively improved the health of persons with non-alcoholic fatty liver disease, a chronic metabolic disorder that affects hundreds of millions of people worldwide.
› Verified 8 days ago
| Entity Name | Regents Of The University Of California |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881763597 PECOS PAC ID: 4284547274 Enrollment ID: O20031106000389 |
News Archive
Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that Dr. Geoffrey I. Shapiro of Dana-Farber Cancer Institute, presented preclinical and clinical data on STA-9090, a potent second-generation Hsp90 inhibitor, at IASLC (International Association for the Study of Lung Cancer) 10th Annual Targeted Therapies of the Treatment of Lung Cancer Meeting in Santa Monica, CA.
The authors of the bestselling EAT THIS, NOT THAT! book series, with more than five million copies in print, today released the ultimate reference book for making the most effective food choices while dining at your favorite restaurants — EAT THIS, NOT THAT! RESTAURANT SURVIVAL GUIDE by David Zinczenko, with Matt Goulding.
Olivier Delattre's team (Inserm Unit 830 "Genetics and Biology of Cancer") of the Institut Curie reveal in an article in the 16 October issue of Nature that alteration of the ALK gene is closely associated with the most frequent solid extracerebral tumor in children-neuroblastoma. By studying the familial forms of this tumor, the researchers also conclude that ALK is a gene that predisposes to neuroblastoma.
Using a first-of-its-class drug in a clinical trial, an international research effort headed by a scientist at University of California San Diego School of Medicine reports that inhibition of a key enzyme safely and effectively improved the health of persons with non-alcoholic fatty liver disease, a chronic metabolic disorder that affects hundreds of millions of people worldwide.
› Verified 8 days ago
| Entity Name | University Of California San Francisco |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861578973 PECOS PAC ID: 4486567229 Enrollment ID: O20031212000897 |
News Archive
Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that Dr. Geoffrey I. Shapiro of Dana-Farber Cancer Institute, presented preclinical and clinical data on STA-9090, a potent second-generation Hsp90 inhibitor, at IASLC (International Association for the Study of Lung Cancer) 10th Annual Targeted Therapies of the Treatment of Lung Cancer Meeting in Santa Monica, CA.
The authors of the bestselling EAT THIS, NOT THAT! book series, with more than five million copies in print, today released the ultimate reference book for making the most effective food choices while dining at your favorite restaurants — EAT THIS, NOT THAT! RESTAURANT SURVIVAL GUIDE by David Zinczenko, with Matt Goulding.
Olivier Delattre's team (Inserm Unit 830 "Genetics and Biology of Cancer") of the Institut Curie reveal in an article in the 16 October issue of Nature that alteration of the ALK gene is closely associated with the most frequent solid extracerebral tumor in children-neuroblastoma. By studying the familial forms of this tumor, the researchers also conclude that ALK is a gene that predisposes to neuroblastoma.
Using a first-of-its-class drug in a clinical trial, an international research effort headed by a scientist at University of California San Diego School of Medicine reports that inhibition of a key enzyme safely and effectively improved the health of persons with non-alcoholic fatty liver disease, a chronic metabolic disorder that affects hundreds of millions of people worldwide.
› Verified 8 days ago
| Entity Name | Ucsf Medical Group Business Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477624104 PECOS PAC ID: 3779497870 Enrollment ID: O20040622001513 |
News Archive
Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that Dr. Geoffrey I. Shapiro of Dana-Farber Cancer Institute, presented preclinical and clinical data on STA-9090, a potent second-generation Hsp90 inhibitor, at IASLC (International Association for the Study of Lung Cancer) 10th Annual Targeted Therapies of the Treatment of Lung Cancer Meeting in Santa Monica, CA.
The authors of the bestselling EAT THIS, NOT THAT! book series, with more than five million copies in print, today released the ultimate reference book for making the most effective food choices while dining at your favorite restaurants — EAT THIS, NOT THAT! RESTAURANT SURVIVAL GUIDE by David Zinczenko, with Matt Goulding.
Olivier Delattre's team (Inserm Unit 830 "Genetics and Biology of Cancer") of the Institut Curie reveal in an article in the 16 October issue of Nature that alteration of the ALK gene is closely associated with the most frequent solid extracerebral tumor in children-neuroblastoma. By studying the familial forms of this tumor, the researchers also conclude that ALK is a gene that predisposes to neuroblastoma.
Using a first-of-its-class drug in a clinical trial, an international research effort headed by a scientist at University of California San Diego School of Medicine reports that inhibition of a key enzyme safely and effectively improved the health of persons with non-alcoholic fatty liver disease, a chronic metabolic disorder that affects hundreds of millions of people worldwide.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Lin Shen, MD, PHD 400 Parnassus Ave # U384, San Francisco, CA 94143-2202 Ph: (415) 353-2497 | Dr Lin Shen, MD, PHD 400 Parnassus Ave # U384, San Francisco, CA 94143-2202 Ph: (415) 353-2497 |
News Archive
Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that Dr. Geoffrey I. Shapiro of Dana-Farber Cancer Institute, presented preclinical and clinical data on STA-9090, a potent second-generation Hsp90 inhibitor, at IASLC (International Association for the Study of Lung Cancer) 10th Annual Targeted Therapies of the Treatment of Lung Cancer Meeting in Santa Monica, CA.
The authors of the bestselling EAT THIS, NOT THAT! book series, with more than five million copies in print, today released the ultimate reference book for making the most effective food choices while dining at your favorite restaurants — EAT THIS, NOT THAT! RESTAURANT SURVIVAL GUIDE by David Zinczenko, with Matt Goulding.
Olivier Delattre's team (Inserm Unit 830 "Genetics and Biology of Cancer") of the Institut Curie reveal in an article in the 16 October issue of Nature that alteration of the ALK gene is closely associated with the most frequent solid extracerebral tumor in children-neuroblastoma. By studying the familial forms of this tumor, the researchers also conclude that ALK is a gene that predisposes to neuroblastoma.
Using a first-of-its-class drug in a clinical trial, an international research effort headed by a scientist at University of California San Diego School of Medicine reports that inhibition of a key enzyme safely and effectively improved the health of persons with non-alcoholic fatty liver disease, a chronic metabolic disorder that affects hundreds of millions of people worldwide.
› Verified 8 days ago
Dr. Pratyusha Kishore Narra, MBBS Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 3490 California St, San Francisco, CA 94118 Phone: 415-514-6200 Fax: 415-514-6410 | |
Dr. Chelsea Joy Thomsen, M.D., M.S.P.H Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 2 W Portal Ave, San Francisco, CA 94127 Phone: 415-291-0480 | |
Christine Soran, Rheumatology Medicare: Medicare Enrolled Practice Location: 1001 Potrero Ave, Bldg 10, 3rd Floor, Ward 13, Ucsf Division Of General Internal Medicine Sfgh, San Francisco, CA 94110 Phone: 415-206-5164 Fax: 415-206-5586 | |
Stephen Norris Cohen, MD Rheumatology Medicare: Not Enrolled in Medicare Practice Location: 40 Ventura Ave, San Francisco, CA 94116 Phone: 415-681-2171 Fax: 415-681-2171 | |
Mauricio Jalife Bucay, M.D Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 505 Parnassus Ave, San Francisco, CA 94143 Phone: 415-750-4994 Fax: 415-750-8156 | |
Dr. Adriana A.t. Martin, M.D., PH.D. Rheumatology Medicare: Medicare Enrolled Practice Location: 505 Parnassus Ave, San Francisco, CA 94143 Phone: 415-514-7288 | |
Dr. Alexandra Cristina Villasante Fricke, MD Rheumatology Medicare: Medicare Enrolled Practice Location: 655 Montgomery St Ste 810, San Francisco, CA 94111 Phone: 844-847-8216 Fax: 415-520-9150 |